Implementing long-acting injectable antiretroviral treatments in Senegal: issues, challenges and conditions for introducing them. Qualitative study with healthcare providers and patients

References

• Alfieri, C. (2021). Entre vaccin et injections retard d’ARV. Attentes de guérison des femmes vivant avec le VIH à Bobo-Dioulasso, Burkina Faso. In A. Desclaux, A. Diarra, & S. Musso (Éds.), Guérir en Afrique. Promesses et transformations (pp. 213–232). L’Harmattan.
   Google Scholar
• Beckmann, N. (2013). Responding to medical crises: AIDS treatment, responsibilisation and the logic of choice. Anthropology & Medicine, 20(2), 160–174. https://doi.org/10.1080/13648470.2013.800805
   PubMed Web of Science ®Google Scholar
• Bierlich, B. (2000). Injections and the fear of death: An essay on the limits of biomedicine among the Dagomba of northern Ghana. Social Science & Medicine, 50(5), 703–713. https://doi.org/10.1016/S0277-9536(99)00322-6
   PubMed Web of Science ®Google Scholar
• Bland, S., & Crowley, J. (2018). Long-acting HIV treatment and prevention are coming. Preparing for potential game changers. Georgetown Law: O’Neill Institute for National and Global Health Law. https://www.amfar.org/wp-content/uploads/2022/03/overviewpdf-4.pdf
   Google Scholar
• Carillon, S. (2011). Les ruptures de suivi médical des personnes vivant avec le VIH à Kayes (Mali). Approche anthropologique. Sciences sociales et santé, 29(2), 5. https://doi.org/10.3917/sss.292.0005
   Web of Science ®Google Scholar
• Carillon, S., Gallardo, L., Linard, F., Chakvetadze, C., Viard, J.-P., Cros, A., Molina, J.-M., & Slama, L. (2020). Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: Understanding potential users’ ambivalences. AIDS Care, 32(suppl. 2), 155–161https://doi.org/10.1080/09540121.2020.1742869
   PubMedGoogle Scholar
• Chandiwana, N. C., Serenata, C. M., Owen, A., Rannard, S., Pérez Casas, C., Scott, C., Hill, A., Clayden, P., & Flexner, C. (2021). Impact of long-acting therapies on the global HIV epidemic. Aids (London, England), 35(Supplement 2), S137. https://doi.org/10.1097/QAD.0000000000003102
   PubMedGoogle Scholar
• Coutherut, J., Desclaux, A. & Groupe d’étude ANRS 1215 (2014). Le partage du statut sérologique des personnes vivant avec le VIH à 10 ans de traitement antirétroviral au Sénégal. Bulletin de la Société de pathologie exotique, 107(4), 266–272. https://doi.org/10.1007/s13149-014-0343-z
   PubMedGoogle Scholar
• Cresswell, F. V., & Lamorde, M. (2022). Implementation of long-acting antiretroviral therapy in low-income and middle-income countries. Current Opinion in HIV and AIDS, 17(3), 127–134. https://doi.org/10.1097/COH.0000000000000732
   PubMed Web of Science ®Google Scholar
• Dandachi, D., Dang, B. N., Lucari, B., Swindells, S., & Giordano, T. P. (2021). Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. AIDS Care, 33(6), 801–809. https://doi.org/10.1080/09540121.2020.1764906
   PubMed Web of Science ®Google Scholar
• David, P.-M. (2019). “Ce sont maintenant les résistances qui vont nous tuer”. Insécurités pharmaceutiques, ruptures de stock et résistances aux traitements contre le VIH en Afrique centrale. Anthropologie & Santé. Revue internationale francophone d’anthropologie de la santé [En ligne], 19, https://doi.org/10.4000/anthropologiesante.4643
   Google Scholar
• Decroo, T., Rasschaert, F., Telfer, B., Remartinez, D., Laga, M., & Ford, N. (2013). Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: A systematic review. International Health, 5(3), 169–179. https://doi.org/10.1093/inthealth/iht016
   PubMed Web of Science ®Google Scholar
• Desclaux, A., & Egrot, M. (eds.). (2015). Anthropologie du médicament au sud: La pharmaceuticalisation à ses marges. L’Harmattan.
   Google Scholar
• Desclaux, A., Laniece, I., Ndoye, I., & Taverne, B. (eds.). (2002). L’Initiative sénégalaise d’accès aux médicaments antirétroviraux. Analyses économiques, sociales, comportementales et médicales. ANRS. http://www.ird.sn/activites/sida/pdf/ISAARV.pdf
   Google Scholar
• Eshun-Wilson, I., Rohwer, A., Hendricks, L., Oliver, S., & Garner, P. (2019). Being HIV positive and staying on antiretroviral therapy in Africa: A qualitative systematic review and theoretical model. PloS One, 14(1), e0210408. https://doi.org/10.1371/journal.pone.0210408
   PubMed Web of Science ®Google Scholar
• Hardon, A. (2015). Les usages comparés des contraceptifs dans trois pays: Pays-Bas, Philippines, Afrique du Sud. In A. Desclaux & M. Egrot (Eds.), Anthropologie du médicament au Sud. La pharmaceuticalisation à ses marges (pp. 219–234). L’Harmattan.
   Google Scholar
• Kerrigan, D., Karver, T. S., Muraleetharan, O., Savage, V., Mbwambo, J., Donastorg, Y., Likindikoki, S., Perez, M., Gomez, H., Mantsios, A., Murray, M., Beckham, S. W., Davis, W., Galai, N., & Barrington, C. (2020). “A dream come true”: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLOS ONE, 15(6), e0234666. https://doi.org/10.1371/journal.pone.0234666
   Web of Science ®Google Scholar
• Kerrigan, D., Mantsios, A., Gorgolas, M., Montes, M.-L., Pulido, F., Brinson, C., de Vente, J., Richmond, G. J., Beckham, S. W., Hammond, P., Margolis, D., & Murray, M. (2018). Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLOS ONE, 13 (1), e0190487. https://doi.org/10.1371/journal.pone.0190487
   PubMed Web of Science ®Google Scholar
• Kotwal, A. (2005). Innovation, diffusion and safety of a medical technology: A review of the literature on injection practices. Social Science & Medicine, 60(5), 1133–1147. https://doi.org/10.1016/j.socscimed.2004.06.044
   PubMed Web of Science ®Google Scholar
• Lachenal, G. (2014). Le médicament qui devait sauver l’Afrique (La Découverte). https://www.editionsladecouverte.fr/le_medicament_qui_devait_sauver_l_afrique-9782359250879
   Google Scholar
• Mantsios, A., Murray, M., Karver, T. S., Davis, W., Galai, N., Kumar, P., Swindells, S., Bredeek, U. F., García, R. R., Antela, A., Gomis, S. C., Bernáldez, M. P., Czarnogorski, M., Hudson, K., Walters, N., & Kerrigan, D. (2021). Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: Perspectives of health care providers participating in phase 3 trials. BMC Health Services Research, 21(1), 255. https://doi.org/10.1186/s12913-021-06214-9
   PubMed Web of Science ®Google Scholar
• Mantsios, A., Murray, M., Karver, T. S., Davis, W., Margolis, D., Kumar, P., Swindells, S., Bredeek, U. F., García Del Toro, M., Garcia Gasalla, M., Rubio García, R., Antela, A., Hudson, K., Griffith, S., & Kerrigan, D. (2020). Efficacy and freedom: Patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of phase 3 trials. AIDS and Behavior, 24(12), 3473–3481. https://doi.org/10.1007/s10461-020-02918-x
   PubMed Web of Science ®Google Scholar
• Margolis, D. A., Gonzalez-Garcia, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., Gutierrez, F., Sloan, L., Clair, M. S., Murray, M., Ford, S. L., Mrus, J., Patel, P., Crauwels, H., Griffith, S. K., … Spreen, W. R. (2017). Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. The Lancet, 390(10101), 1499–1510. https://doi.org/10.1016/S0140-6736(17)31917-7
   PubMed Web of Science ®Google Scholar
• Mattes, D. (2014). Caught in transition: The struggle to live a ‘normal’ life with HIV in Tanzania. Medical Anthropology, 33(4), 270–287. https://doi.org/10.1080/01459740.2013.877899
   PubMed Web of Science ®Google Scholar
• Murray, M., Markowitz, M., Frank, I., Grant, R. M., Mayer, K. H., Hudson, K. J., Stancil, B. S., Ford, S. L., Patel, P., Rinehart, A. R., Spreen, W. R., & Margolis, D. A. (2018). Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clinical Trials, 19(4), 129–138. https://doi.org/10.1080/15284336.2018.1511346
   PubMed Web of Science ®Google Scholar
• Nguyen, V.-K., Bajos, N., Dubois-Arber, F., O'Malley, J., & Pirkle, C. M. (2011). Remedicalizing an epidemic: From HIV treatment as prevention to HIV treatment is prevention. Aids (London, England), 25(3), 291–293. https://doi.org/10.1097/QAD.0b013e3283402c3e
   PubMed Web of Science ®Google Scholar
• Overton, E. T., Richmond, G., Rizzardini, G., Jaeger, H., Orrell, C., Nagimova, F., Bredeek, F., Deltoro, M. G., Swindells, S., Andrade-Villanueva, J. F., Wong, A., Khuong-Josses, M.-A., Solingen-Ristea, R. V., van Eygen, V., Crauwels, H., Ford, S., Talarico, C., Benn, P., Wang, Y., … Spreen, W. (2020). Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet, 396(10267), 1994–2005. https://doi.org/10.1016/S0140-6736(20)32666-0
   PubMed Web of Science ®Google Scholar
• Patton, M. Q. (2002). Qualitative research & evaluation methods (3ème édition). SAGE.
   Google Scholar
• Pepin, J. (2011). The origins of AIDS. Cambridge University Press. https://doi.org/10.1017/CBO9781139005234
   Google Scholar
• Reeler, A. V. (1990). Injections: A fatal attraction? Social Sciences and Medicine, 31(n¡10), 1119–1125. https://doi.org/10.1016/0277-9536(90)90233-I
   PubMedGoogle Scholar
• Simoni, J. M., Beima-Sofie, K., Wanje, G., Mohamed, Z. H., Tapia, K., McClelland, R. S., Ho, R. J. Y., Collier, A. C., & Graham, S. M. (2021). “Lighten this burden of ours”: Acceptability and preferences regarding injectable antiretroviral treatment among adults and youth living with HIV in Coastal Kenya. Journal of the International Association of Providers of AIDS Care (JIAPAC), 20, 232595822110005. https://doi.org/10.1177/23259582211000517
   PubMedGoogle Scholar
• Sued, O., Nardi, N., & Spadaccini, L. (2022). Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: A scoping review. Current Opinion in HIV and AIDS, 17(3), 145–161. https://doi.org/10.1097/COH.0000000000000734
   PubMed Web of Science ®Google Scholar
• Taverne, B., Desclaux, A., Sow, P.-S., Delaporte, E., & Ndoye, I. (2012). Evaluation de l’impact bioclinique et social, individuel et collectif, du traitement ARV chez des patients VIH-1 pris en charge depuis 10 ans dans le cadre de l’ISAARV-Cohorte ANRS 1215. Rapport final.
   Google Scholar
• UNAIDS. (2021a). AIDS_Data_book_2021. https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf
   Google Scholar
• UNAIDS. (2021b). Country factsheets. Senegal. https://www.unaids.org/en/regionscountries/countries/senegal
   Google Scholar
• Van den Hoed, M. W., Backhaus, R., de Vries, E., Hamers, J. P. H., & Daniëls, R. (2022). Factors contributing to innovation readiness in health care organizations: A scoping review. BMC Health Services Research, 22(1), 997. https://doi.org/10.1186/s12913-022-08185-x
   PubMed Web of Science ®Google Scholar